Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Corcept Therapeutics Incorporated common stock during the specified Class Period, indicating potential legal issues surrounding the company's New Drug Application for relacorilant [1][5]. Group 1: Lawsuit Details - The class action lawsuit is focused on the period between October 31, 2024, and December 30, 2025, during which Corcept allegedly misrepresented the status of its NDA for relacorilant, claiming strong support from clinical trials while the FDA had raised concerns about the evidence [1][5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees, as compensation may be available through a contingency fee arrangement [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a notable $438 million secured for investors in 2019 [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors have the option to select their counsel or remain absent from the class at this stage [7].

Core Points - Rosen Law Firm is reminding purchasers of CoreWeave, Inc. securities from March 28, 2025, to December 15, 2025, about the lead plaintiff deadline on March 13, 2026 [1] - Investors who purchased CoreWeave securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed against CoreWeave, and interested parties can join by contacting Rosen Law Firm [3][6] Case Details - The lawsuit alleges that CoreWeave's defendants made false or misleading statements regarding the company's ability to meet customer demand and understated risks associated with reliance on a single third-party data center supplier [5] - It is claimed that these misrepresentations were likely to have a material negative impact on CoreWeave's revenue, leading to damages for investors when the truth was revealed [5] Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions, as many firms issuing notices may lack the necessary experience [4] - Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of GSI Technology Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Legal Action - Rosen Law Firm is preparing a class action to seek recovery of investor losses for those who purchased GSI Technology securities, with no out-of-pocket fees through a contingency fee arrangement [2]. - Investors are encouraged to join the prospective class action by contacting Rosen Law Firm [2]. Group 2: Stock Price Impact - Following allegations that GSI Technology may have misrepresented its chip capabilities, the company's stock price fell by $1.08 per share, or 14.2%, closing at $6.52 per share on February 4, 2026 [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Smart Digital Group Ltd. (NASDAQ: SDM) between May 5, 2025, and September 26, 2025, of the upcoming lead plaintiff deadline on March 16, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased SDM securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by March 16, 2026 [3]. Group 2: Case Allegations - The lawsuit alleges that Smart Digital was involved in a market manipulation and fraudulent promotion scheme, which included misinformation on social media and impersonators posing as financial professionals [5]. - It is claimed that insiders used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [5]. - The public statements and risk disclosures from Smart Digital allegedly omitted critical information regarding the risks of fraudulent trading and market manipulation, leading to misleading representations about the company's business and prospects [5].

Core Insights - Biocytogen Pharmaceuticals has announced that its partner IDEAYA Biosciences has initiated the first patient dosing in a Phase 1 clinical trial for IDE034, a bispecific antibody-drug conjugate targeting B7H3/PTK7 [1] Company Summary - Biocytogen Pharmaceuticals is a global biotechnology company focused on the research and development of novel antibody-based drugs utilizing innovative technologies [1] - IDEAYA Biosciences, a partner of Biocytogen, is conducting the clinical trial for IDE034, which is currently in the dose-escalation and expansion phase [1]

Core Viewpoint - A class action lawsuit has been filed against Oracle Corporation for alleged misleading statements regarding its AI infrastructure strategy and its financial implications during the Class Period from June 12, 2025, to December 16, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Oracle's AI infrastructure strategy would lead to significant increases in capital expenditures without corresponding near-term revenue growth [5]. - It is alleged that Oracle's increased spending poses risks to its debt, credit rating, free cash flow, and project funding capabilities [5]. - The lawsuit asserts that the defendants' statements about Oracle's business and prospects were materially false and misleading, resulting in investor damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased Oracle common stock during the Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the Court by April 6, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, highlighting its effectiveness in representing shareholder interests [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. between September 24, 2025, and October 31, 2025, about the upcoming lead plaintiff deadline on April 13, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought uniQure shares during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3]. - To serve as lead plaintiff, individuals must file with the court by April 13, 2026, acting on behalf of other class members [3]. Group 2: Case Background - The lawsuit alleges that uniQure misrepresented and/or failed to disclose critical information regarding its Pivotal Study for a drug candidate aimed at Huntington's Disease, including FDA approval status and the potential delay in its Biologics License Application (BLA) timeline [5]. - The defendants allegedly downplayed the likelihood of needing additional studies, which led to misleading statements about uniQure's business and prospects [5]. - The lawsuit claims that when the true details became known, investors suffered damages [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

New York, New York--(Newsfile Corp. - February 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of KDDI Corporation (OTC Pink: KDDIY) resulting from allegations that KDDI may have issued materially misleading business information to the investing public.SO WHAT: If you purchased KDDI securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PomDoctor Ltd. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought PomDoctor securities between October 9, 2025, and December 11, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 7, 2026 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that PomDoctor's management made false and misleading statements, failed to disclose a fraudulent stock promotion scheme, and omitted critical information regarding share dumping and artificial trading activity [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased BellRing Brands, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the BellRing Brands securities is from November 19, 2024, to August 4, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by March 23, 2026, to serve as lead plaintiff [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3] Group 3: Case Background - BellRing Brands develops and sells "convenient nutrition" products, primarily under the Premier Protein brand [4] - During the Class Period, BellRing's management claimed that sales growth was due to increased consumer demand and other positive factors, while downplaying competitive pressures [4] - The lawsuit alleges that actual sales were driven by inventory stockpiling by key customers, not by genuine consumer demand, leading to investor damages when the truth was revealed [4]